Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663785 | 0.88 | ITGB3 (0.52) | ITGB3ITGA2BCA12CA1CA2 | |
| SCHEMBL17592938 | 0.84 | CTSS (0.49) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL1185840 | 0.83 | SYK (0.57) | EPHX2PPARGPPARASYK | |
| SCHEMBL1826658 | 0.83 | PPARG (0.44) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL6715192 | 0.82 | CA12 (0.52) | ITGB3ITGA2BCA12CA1CA2 | |
| SCHEMBL2799915 | 0.81 | EPHX2 (0.59) | EPHX2PPARGPPARASYK | |
| Trifluoroacetic Acid SCHEMBL7348672 | 0.79 | SYK (0.53) | EPHX2PPARGSYK | |
| SCHEMBL1826974 | 0.79 | P2RX7 (0.49) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL3574216 | 0.79 | P2RX7 (0.47) | EPHX2PPARGPPARASYK | |
| SCHEMBL6716371 | 0.78 | PTGES (0.55) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | ITGB3 4495/4885ITGA2B 4623/4885CA12 4300/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | ITGB3 4617/4885ITGA2B 4480/4885CA12 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.